cbdMD'S Human Clinical Study Demonstrates Strong Pain Benefits
08:51 Share

Initial Results from the First of Its Kind Clinical Study Demonstrate cbdMD's Proprietary Broad Spectrum Hemp Extract Reduces Pain in Healthy Adults.

Charlotte, North Carolina--(Newsfile Corp. - November 17, 2022) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces the first results from its recently concluded human clinical trial conducted at the University of South Carolina. These studies began in the fall of 2020 and the first results to be reported show the Company's proprietary broad spectrum hemp extract reduces pain in healthy adults. The ground breaking randomized, double blind, placebo controlled study was designed to explore the effects of cbdMD's proprietary broad spectrum cannabinoid blend on sleep, immunity, inflammation, mood, and pain in healthy adult subjects to further support the efficacy of the Company's products.

The Company and its subsidiary cbdMD Therapeutics, LLC will be releasing further results from the human clinical as they are finalized over the next few weeks and will eventually be publishing the results in a peer reviewed journal. The Company anticipates these favorable outcomes will form the basis for a number of future cbdMD product formulations. The study's results will also serve as preliminary data for additional future investigational studies executed by cbdMD's Therapeutics Division.

Study participants were given cbdMD's proprietary broad spectrum hemp extract blend containing 100 mg of CBD and other minor cannabinoids once per day for three months. The first results coming out of the study show that the perception and intensity of pain in healthy adults is significantly reduced with daily consumption of the Company's flagship broad spectrum blend. In anticipation of these results, the Company has recently launched a new flagship product in tincture, gummy and softgel which contains the clinically studied broad spectrum hemp extract blend containing 100 mg per serving of CBD. The flagship blend is contained in all of the Company's broad spectrum products, including its industry first NSF for Sport products. In order to make these efficacious products available to more people in need, the Company has repositioned itself to be CBD brand of choice by providing the highest potency products at the best value in the industry.

"Once published, the data from this study will be submitted to the Food and Drug Administration (FDA) for Structure Function Claim Notifications (SFCNs), the process whereby manufacturers inform FDA of their intent to make statements about their products' benefits on the structure or function of their body," said Lance Blundell, cbdMD's General Counsel and Co-Chair of cbdMD Therapeutics, LLC. "cbdMD leads the industry with our commitment to science. We also lead the industry with our belief that as a responsible and trusted dietary supplement manufacturer we must comply with all applicable regulations. We have conducted the required toxicological studies and we have now completed the required human clinical in order to make structure function claims about our proprietary CBD products. We hold a firm belief that our products are not drug precluded as the Citizen's Petition we filed earlier this year stated. Therefore, we will submit our SFCNs to the FDA as all federally compliant dietary

Powered by KISS PR Brand Story Press Release Distribution )- Hosted by Qamar Zaman

Instagram Qamar Zaman Official )Qamar Zaman on Forbes )